1. Pink Sheet
  2. >>Geography
  3. >>Europe

European Commission Dangles Conditional Approval Reprieve For PTC Therapeutics’ Translarna

 
• By Francesca Bruce

Scientific questions from member state experts and a recent court ruling on impartiality in the drug approval process prompted the European Commission to query the EMA’s negative opinion on PTC’s Translarna.

Bright horizon
A Brighter future for PTC's Translarna is possible after the European Commission has returned CHMP negative opinion • Source: Shutterstock

In a very rare move, the European Commission has rejected advice from the European Medicines Agency not to renew the conditional marketing authorization (CMA) for PTC Therapeutics’ rare disease treatment Translarna (ataluren), the first ever treatment approved for Duchenne muscular dystrophy.

The commission has asked the EMA to review its scientific assessment of the drug following scientific questions from EU member...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

HTA Expert Warns of Escalating Measures if Pharma Fails to Tame Prices

 
• By Francesca Bruce

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.

EU Tests Unified Pathway For Combined Drug/IVD Studies

 
• By Vibha Sharma

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.

More from Geography